Latest News

Mazen M. Dimachkie, MD  (Credit: University of Kansas Medical Center)
Cipaglucosidase Alfa/Miglustat Therapy Improves Efficacy Outcomes in Enzyme Replacement Therapy-Experienced Patients With Late-Onset Pompe Disease

October 15th 2024

A new analysis of the phase 3 PROPEL study showed that switching to cipaglucosidase alfa/miglustat therapy enhanced outcomes among patients with late-onset Pompe disease.

Sarosh Ahmed, PT, DPT, CBIS-T  (Credit: X)
Meta-Analysis Reveals Significant Burden of Cardiovascular Comorbidities in Myasthenia Gravis

October 15th 2024

Jeffrey Rothstein, MD, PhD  (Credit: Johns Hopkins Medicine)
Daily Oral Edaravone Fails to Display Superiority in Phase 3B Study MT-1186-A02 for ALS

October 15th 2024

Understanding the Therapeutic Potential of GT-02287 in GBA-Parkinson Disease
Understanding the Therapeutic Potential of GT-02287 in GBA-Parkinson Disease

October 14th 2024

Coverage of the American Association of Neuromuscular & Electrodiagnostic Medicine 2024 Meeting

Get expert-driven insight and coverage of key data and research straight from the conference floor in Savannah.

AANEM 2024

Conference Coverage

View All
Mazen M. Dimachkie, MD  (Credit: University of Kansas Medical Center)
Cipaglucosidase Alfa/Miglustat Therapy Improves Efficacy Outcomes in Enzyme Replacement Therapy-Experienced Patients With Late-Onset Pompe Disease

October 15th 2024

Sarosh Ahmed, PT, DPT, CBIS-T  (Credit: X)
Meta-Analysis Reveals Significant Burden of Cardiovascular Comorbidities in Myasthenia Gravis

October 15th 2024

Jeffrey Rothstein, MD, PhD  (Credit: Johns Hopkins Medicine)
Daily Oral Edaravone Fails to Display Superiority in Phase 3B Study MT-1186-A02 for ALS

October 15th 2024

Video Series
Video Interviews
Podcasts

Most Recent

© 2024 MJH Life Sciences

All rights reserved.